Home | Welcome to Contract Pharma   
Last Updated Monday, March 30 2015


UCB, biOasis In Research Pact

Published December 3, 2012
Related Searches: Drug Delivery
biOasis Technologies and UCB, based in Brussels, have entered into a research collaboration to evaluate biOasis’ Transcend technology for the delivery of therapeutic compounds to the brain. biOasis will conduct certain experiments using its Transcend technology as it relates to the delivery of therapeutic compounds owned by UCB for CNS disorders. Financial Terms were not disclosed.
"UCB is a highly respected biopharmaceutical company with a broad global presence and a deep pipeline. We’re very pleased to be commencing this collaboration with UCB whom we believe have some tremendous targets for our Transcend vector," said Rob Hutchison, chief executive officer, biOasis Technologies. "The interest from within the industry on our Transcend technology is clearly widening and this agreement with UCB is a prime example of that. The work will start over the next few months and carry into the New Year. We are looking forward to working with the UCB scientists to successfully achieve the objectives we have set out in agreement."

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On